Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSY-F roll-over benralizumab continuation study
NL-OMON61437Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of benralizumab in hypereosinophilic syndrome (HES), eosinophilic granulomatosis with polyangiitis (EGPA) and asthma, sponsored by AstraZeneca. Primary endpoint: Safety. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
benralizumab
03
Conditions
hypereosinophilic syndrome (HES)eosinophilic granulomatosis with polyangiitis (EGPA)asthma
Beyond the preview
Go deeper on NL-OMON61437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61437.